Clinical Research Directory

Inclusion Criteria: * Provision of signed and dated informed consent form * Collection of biosamples at baseline (sera, liver cancer and non liver cancer tissues, Peripheral blood mononuclear cells (PBMCs)) each of the 3-month interval follow ups (serum and PBMCs) for a total of 4 during the study follow up duration 1 year post-hepatectomy. * Early-stage HCC eligible for hepatectomy for curative intention. Early HCC (Stage A) is limited to a single tumor \<5 cm in diameter or three tumors that are each \<3cm. * Stated willingness to comply with all study procedures and availability for the duration of the study and up to 3 years post-study follow up * Adults aged 18 or older * Both genders and all ethnicities * Willingness to give written, informed consent to be enrolled into the study database * Reside in Vietnam at the time of study and provides contact information (email and/or cell phone number for texting) * No prior or current treatment of HCC * No cancer history within 5 years * No participation in other trial for HCC Treatment * No significant hepatic decompensation * No hepatorenal syndrome * Alpha fetoprotein (AFP) test labs within 90 days irrespective of AFP titer * Two phone numbers and personal identification numbers (CMND number) * No known AIDS related diseases * No significant co-morbid conditions with life expectancy \<2 years Exclusion Criteria: * Individuals who cannot, do not want to, or refused to sign the informed consent form (ICF) * Any serious or active medical or psychiatric illness, which, in the opinion of the investigator, would interfere with patient treatment, assessment or compliance with the protocol * Documentation was not adequate * Known HIV positive * Taking immunosuppressants * Having any autoimmune diseases based on clinical and/or laboratory availabilities